IGC Pharma Inc. reported its third‑quarter 2025 earnings for the period ended December 31, 2025, posting a net loss of $0.01 per share—an EPS beat of $0.01 versus the consensus estimate of a $0.02 loss. Revenue for the quarter was $213,000, falling short of the $325,000 estimate, but the company’s loss margin narrowed compared with the $5.8 million loss reported for the same quarter in 2023.
The earnings beat was driven largely by disciplined cost management and a one‑time gain from the divestiture of a non‑core manufacturing facility. The sale generated a $2.7 million cash inflow and a $1.1 million non‑cash profit, while the company reduced its annual operating expenses by roughly $600,000. In contrast, research and development spending rose 48% to $4.0 million for the nine‑month period, reflecting intensified investment in the Phase 2 CALMA trial for IGC‑AD1.
Revenue for the quarter was $213,000, below the consensus estimate. While other sources have reported figures ranging from $191,000 to $257,000, the company’s own disclosure lists $213,000. The revenue shortfall reflects a transition from legacy white‑label manufacturing to a focus on its core pharmaceutical and AI assets, a shift that has temporarily compressed top‑line growth but is intended to support long‑term value creation.
"We have surpassed 70% enrollment in the Phase 2 CALMA clinical trial, marking a significant acceleration as the program advances toward key development milestones. CALMA is evaluating our lead candidate, IGC‑AD1, for agitation in Alzheimer’s dementia, a critical area of unmet medical need with a massive global footprint. As we move toward full enrollment and a defined clinical readout, our focus remains on disciplined execution and the creation of long‑term value for our patients and shareholders," said CEO Ram Mukunda.
"The third quarter of fiscal 2025 was marked by our progress in advancing IGC‑AD1 in our Phase 2 CALMA trial aimed at reducing agitation in Alzheimer’s. We are also planning to explore IGC‑AD1 as an Alzheimer’s disease‑modifying therapy, aimed at reducing plaques and tangles in the brain, which positions IGC‑AD1 in a significantly broader market. Our AI‑driven research also gained recognition from the NIH through the PREPARE Challenge, reinforcing our leadership in Alzheimer’s innovation," Mukunda added.
The company’s net loss for the nine‑month period ended December 31, 2025, improved to $4.1 million from $5.9 million a year earlier, and the Q3 loss of $1.8 million narrowed from $5.8 million in the same quarter of 2023. The divestiture and cost‑control measures have begun to offset the higher R&D spend, but the company remains unprofitable. Continued progress in the CALMA trial and the expansion of IGC‑AD1’s therapeutic scope are expected to drive future revenue growth, while the company’s AI platform gains recognition and may open additional commercial opportunities.
The earnings release underscores IGC Pharma’s ongoing transition from a manufacturing‑centric model to a research‑driven, AI‑enabled biopharmaceutical company. While the company’s quarterly revenue remains modest and its losses persist, the narrowing loss margin, improved operating efficiency, and accelerated clinical milestones suggest a strategic shift that could enhance long‑term value if the company’s pipeline advances successfully.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.